MV-ZIKA

ZIKAVAX

at a glance

TARGET DISEASE

Zika virus Disease

TIMELINE

01 October 2016 to 31 December 2020

COORDINATOR

European Vaccine Initiative

FUNDER

European Union

FUNDING

4.9 Mio Euro

SUMMARY

ZIKAVAX

The ZIKAVAX project aims at developing a safe, effective, and affordable preventive vaccine against Zika virus infection. To achieve this goal, ZIKAVAX uses a delivery platform technology based on a measles vector (MV) with demonstrated proof of principle in humans and a preclinical track record of rapid adaptability and effectiveness for a variety of pathogens. In ZIKAVAX, following antigen selection and expression, immunisation studies were conducted with the Zika vaccine candidate in mice and in a non-human primates challenge model that was developed by the consortium. The ultimate goal of ZIKAVAX is the demonstration of safety and immunogenicity of a recombinant measles-Zika vaccine candidate (MV-ZIKA) in adult volunteers in a phase Ia clinical trial.

ZIKAVAX

PARTNERS

Commissariat à l’énergie atomique et aux énergies alternatives (CEA) (France); European Vaccine Initiative (EVI) (Germany); Institut Pasteur (France); Themis Bioscience (Austria).

European Union

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 732432.